📊 IRD Key Takeaways
Is IRD a Good Investment? Thesis Analysis
Opus Genetics is a pre-revenue pharmaceutical company with severe and worsening operational losses, burning $35.3M in operating cash flow against only $14.2M in revenue. While the company maintains adequate liquidity with $45.1M in cash and a strong balance sheet, the trajectory of losses (-$49.6M net income) indicates this is an unprofitable R&D stage biotech firm with a ~1.3 year cash runway at current burn rates.
Why Buy IRD? Key Strengths
- Strong liquidity position with $45.1M in cash and 6.43x current ratio provides runway for operations
- Low leverage with only $1.1M long-term debt and 0.07x debt-to-equity ratio minimizes financial distress risk
- Revenue growing 29.1% YoY demonstrates some commercialization progress in pharmaceutical segment
IRD Investment Risks to Consider
- Massive operating losses of -$38.6M on only $14.2M revenue indicating negative unit economics and unsustainable burn
- Operating cash flow negative -$35.3M with no capital expenditures suggests pure R&D consumption without asset-building
- Cash runway of approximately 15 months at current burn rate creates existential risk unless profitability or funding materializes
- Negative ROE of -323.1% and ROA of -98.7% reflect severe value destruction and unproven business model
- 19 Form 4 insider filings in 90 days warrant scrutiny for potential dilutive issuances or management concern signals
Key Metrics to Watch
- Operating cash flow trend - critical to assess if burn rate is decelerating or accelerating
- Cash balance and runway - must monitor closely given limited liquidity timeline
- Revenue quality and gross margin realization - need to assess profitability of actual revenue generation
- Capital raise activity - likelihood and terms of future dilutive financing
- R&D efficiency metrics - pipeline advancement and probability of successful drug approvals
IRD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.43x current ratio provides a solid financial cushion.
IRD Profitability Ratios
IRD vs Healthcare Sector
How Opus Genetics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRD Overvalued or Undervalued?
Based on fundamental analysis, Opus Genetics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRD Balance Sheet & Liquidity
IRD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Opus Genetics, Inc.'s revenue has grown significantly by 2,310% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.15 indicates the company is currently unprofitable.
IRD Growth Metrics (YoY)
IRD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.1M | -$7.1M | $-0.25 |
| Q2 2025 | $1.1M | -$7.1M | $-0.12 |
| Q1 2025 | $1.7M | -$7.1M | $-0.24 |
| Q3 2024 | $3.9M | -$5.0M | $-0.25 |
| Q2 2024 | $1.1M | -$5.0M | $-0.24 |
| Q1 2024 | $1.7M | -$5.8M | $-0.28 |
| Q3 2023 | N/A | -$4.5M | $-0.22 |
| Q2 2023 | N/A | -$4.9M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IRD Capital Allocation
IRD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Opus Genetics, Inc. (CIK: 0001228627)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRD
What is the AI rating for IRD?
Opus Genetics, Inc. (IRD) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRD's key strengths?
Claude: Strong liquidity position with $45.1M in cash and 6.43x current ratio provides runway for operations. Low leverage with only $1.1M long-term debt and 0.07x debt-to-equity ratio minimizes financial distress risk.
What are the risks of investing in IRD?
Claude: Massive operating losses of -$38.6M on only $14.2M revenue indicating negative unit economics and unsustainable burn. Operating cash flow negative -$35.3M with no capital expenditures suggests pure R&D consumption without asset-building.
What is IRD's revenue and growth?
Opus Genetics, Inc. reported revenue of $14.2M.
Does IRD pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
Where can I find IRD SEC filings?
Official SEC filings for Opus Genetics, Inc. (CIK: 0001228627) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRD's EPS?
Opus Genetics, Inc. has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRD a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Opus Genetics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRD stock overvalued or undervalued?
Valuation metrics for IRD: ROE of -323.1% (sector avg: 15%), net margin of -349.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRD stock in 2026?
Our dual AI analysis gives Opus Genetics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRD's free cash flow?
Opus Genetics, Inc.'s operating cash flow is $-35.3M, with capital expenditures of $0.0. FCF margin is -248.3%.
How does IRD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -349.3% (avg: 12%), ROE -323.1% (avg: 15%), current ratio 6.43 (avg: 2).